Curis Lifesciences Limited (NSE:CURIS)
India · Delayed Price · Currency is INR 165.70
+14.35 (9.48%)
At close: Sep 7, 2026
Curis Lifesciences Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 31.65 | 3.04 | 4.18 | 1.52 | 1.11 |
Cash & Short-Term Investments | 31.65 | 3.04 | 4.18 | 1.52 | 1.11 |
Cash Growth | 942.52% | -27.28% | 174.13% | 37.33% | -4.64% |
Accounts Receivable | 112.23 | 75.24 | 100.96 | 95.46 | 62.44 |
Other Receivables | - | 20.45 | 18.68 | 22.75 | 29.61 |
Receivables | 318.67 | 95.68 | 119.64 | 118.2 | 92.12 |
Inventory | 341.09 | 184 | 89.62 | 51.08 | 53.75 |
Prepaid Expenses | - | 8.97 | 0.43 | 0.52 | 0.77 |
Other Current Assets | - | 21.24 | 7.24 | 2.43 | 1.03 |
Total Current Assets | 691.41 | 312.93 | 221.1 | 173.75 | 148.78 |
Property, Plant & Equipment | 121.05 | 110.1 | 115.92 | 121.98 | 123.34 |
Long-Term Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
Other Long-Term Assets | 2.71 | 2.27 | 1.7 | 1.7 | 1.82 |
Total Assets | 815.21 | 425.35 | 338.76 | 297.48 | 273.99 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | 81.81 | 51.61 | 62.29 | 101.56 | 85.35 |
Accrued Expenses | - | 18.86 | 13.73 | 16.79 | 17.03 |
Short-Term Debt | 160.11 | 71.56 | 71.31 | 50.88 | 36 |
Current Portion of Long-Term Debt | - | 9.63 | 12.57 | 13.3 | 16.19 |
Current Income Taxes Payable | - | 22.71 | 15.56 | - | - |
Other Current Liabilities | 32.12 | 1.4 | 6.57 | 3.07 | 3.55 |
Total Current Liabilities | 274.04 | 175.77 | 182.03 | 185.6 | 158.12 |
Long-Term Debt | 55.8 | 74.99 | 87.01 | 97.75 | 124.05 |
Pension & Post-Retirement Benefits | 0.47 | 1.45 | 0.2 | 0.16 | 0.1 |
Long-Term Deferred Tax Liabilities | 11.33 | 10.87 | 10.79 | 3.9 | 0.75 |
Other Long-Term Liabilities | -0 | -0 | - | - | - |
Total Liabilities | 341.63 | 263.07 | 280.04 | 287.42 | 283.02 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 80.84 | 59.34 | 5 | 5 | 5 |
Additional Paid-In Capital | - | 42.1 | - | - | - |
Retained Earnings | - | 60.83 | 53.73 | 5.06 | -14.04 |
Comprehensive Income & Other | 392.73 | 0 | - | - | - |
Shareholders' Equity | 473.58 | 162.28 | 58.73 | 10.06 | -9.04 |
Total Liabilities & Equity | 815.21 | 425.35 | 338.76 | 297.48 | 273.99 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | 215.91 | 156.18 | 170.89 | 161.93 | 176.24 |
Net Cash (Debt) | -184.26 | -153.14 | -166.72 | -160.41 | -175.13 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -27.33 | -25.81 | -28.28 | -27.21 | -31.84 |
Filing Date Shares Outstanding | 6.74 | 5.93 | 5.5 | 5.5 | 5.5 |
Total Common Shares Outstanding | 6.74 | 5.93 | 5.5 | 5.5 | 5.5 |
Working Capital | 417.37 | 137.16 | 39.07 | -11.86 | -9.34 |
Book Value Per Share | 70.25 | 27.34 | 10.68 | 1.83 | -1.64 |
Tangible Book Value | 473.58 | 162.28 | 58.73 | 10.06 | -9.04 |
Tangible Book Value Per Share | 70.25 | 27.34 | 10.68 | 1.83 | -1.64 |
Land | - | 9.41 | 9.16 | 8.87 | 7.37 |
Buildings | - | 42.79 | 42.79 | 42.79 | 42.79 |
Machinery | - | 108.4 | 107.88 | 107.43 | 103.32 |
Construction In Progress | - | 0.15 | - | - | - |